Adaptimmune Therapeutics plc

  • Home
  • Our Company
    • Overview arrow_forward
    • Partners arrow_forward
    • Board of Directors arrow_forward
    • Leadership Team arrow_forward
    • Scientific Advisory Board arrow_forward
    • Perspectives arrow_forward
    • COVID-19 arrow_forward
  • Pipeline
    • Overview arrow_forward
    • ADP-A2M4 arrow_forward
    • ADP-A2M4CD8 arrow_forward
    • ADP-A2AFP arrow_forward
    • ADP-A2M10 arrow_forward
  • Technology
    • Overview arrow_forward
    • Manufacturing arrow_forward
    • Publications arrow_forward
  • Patients & Families
    • Overview arrow_forward
    • Taking Part in Our Clincial Trials arrow_forward
    • Cancer Info arrow_forward
    • Cancer Immunotherapy Month arrow_forward
    • Videos arrow_forward
    • Engagement with Patient Organizations arrow_forward
  • Clinical Trials
  • Investors & Media
    • Overview arrow_forward
    • News & Events arrow_forward
    • Annual Shareholder Meeting arrow_forward
    • Company Info arrow_forward
    • Financial Info arrow_forward
    • Stock Data arrow_forward
    • SEC Filings arrow_forward
    • Governance arrow_forward
    • Media arrow_forward
  • Contact
  • Careers
    • Overview arrow_forward
    • U.S. Careers arrow_forward
    • UK Careers arrow_forward

Press Releases

Investors & Media

Investors & Media

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Annual Shareholder Meeting
  • Company Info
    • Overview
    • Leadership Team
    • Board of Directors
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Media
  • News & Media

  • Press Releases
  • Presentations
  • Events
Nov 16, 2019 2:00am EST

Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma

Nov 06, 2019 7:30am EST

Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update

Nov 01, 2019 8:00am EDT

Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019

Oct 09, 2019 8:00am EDT

Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies

Oct 01, 2019 8:00am EDT

Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer

Sep 30, 2019 8:45am EDT

Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO

Sep 09, 2019 8:00am EDT

United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4

Aug 27, 2019 8:00am EDT

Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients

Aug 01, 2019 7:15am EDT

New Executive Team Announced at Adaptimmune

Aug 01, 2019 7:15am EDT

Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update

RSS
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...19
  • Next
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
Adaptimmune Therapeutics plc
Privacy Policy Disclaimer Search Sitemap Terms of Use Supply Terms
Linedin Twitter Youtube
© 2021 Adaptimmune Therapeutics plc. All Rights Reserved.